GlycoMimetics (NASDAQ:GLYC – Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05, Zacks reports.
GlycoMimetics Stock Up 2.2 %
NASDAQ:GLYC opened at $0.29 on Friday. GlycoMimetics has a fifty-two week low of $0.14 and a fifty-two week high of $3.36. The firm’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.24.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of GlycoMimetics in a research note on Monday, February 10th. They issued a “sell” rating on the stock.
About GlycoMimetics
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Read More
- Five stocks we like better than GlycoMimetics
- Using the MarketBeat Stock Split Calculator
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Profitably Trade Stocks at 52-Week Highs
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What is a Special Dividend?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
